
Flagship Pioneering launches Terrana Biosciences with $50m investment
Terrana Biosciences will develop crop protection inputs using RNA technology, which was used by Flagship portfolio company Moderna to develop its covid-19 vaccine.
Terrana Biosciences will develop crop protection inputs using RNA technology, which was used by Flagship portfolio company Moderna to develop its covid-19 vaccine.
Copyright PEI Media
Not for publication, email or dissemination